Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer

Jia-Rong Huang,Sheng-Te Wang,Meng-Ning Wei,Kun Liu,Jing-Wen Fu,Zi-Hao Xing,Zhi Shi
DOI: https://doi.org/10.3389/fphar.2020.586885
IF: 5.6
2020-11-12
Frontiers in Pharmacology
Abstract:Colorectal cancer is one of the most common and lethal cancers in the world. An important causative factor of colorectal cancer is ulcerative colitis. In this study, we investigated the therapeutic effects of piperlongumine (PL) on the dextran sulfate sodium (DSS)-induced acute colitis and azoxymethane (AOM)/DSS-induced colorectal cancer mouse models. Our results showed that PL could inhibit the inflammation of DSS-induced mouse colitis and reduce the number of large neoplasms (diameter >2 mm) of AOM/DSS-induced mouse colorectal cancer by downregulation of proinflammatory cytokines cyclooxygenase-2 and interleukin-6 and epithelial-mesenchymal transition-related factors, β-catenin, and snail expressions, but fail to improve the colitis symptoms and to decrease the incidence of colonic neoplasms and the number of small neoplasms (diameter <2 mm). These data suggested that PL might be an effective agent in treating colitis and colorectal cancer.
pharmacology & pharmacy
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to evaluate the efficacy of piperlongumine (PL) in the treatment of acute colitis in mice induced by dextran sulfate sodium (DSS) and colorectal cancer in mice induced by azoxymethane (AOM)/DSS. Specifically, the study aims to explore whether PL can alleviate the symptoms of DSS - induced acute colitis and reduce the occurrence and development of tumors in the AOM/DSS - induced mouse model of colorectal cancer. Inhibition of inflammation and control of tumor growth are achieved by down - regulating the expression of pro - inflammatory cytokines such as cyclooxygenase - 2 (COX - 2) and interleukin - 6 (IL - 6), as well as epithelial - mesenchymal transition - related factors such as β - catenin and Snail. The main findings of the paper include: - PL can inhibit the inflammatory response in DSS - induced colitis in mice, but fails to improve colitis symptoms or increase colon length. - In the AOM/DSS - induced colorectal cancer model, PL significantly reduces the number of large tumors with a diameter greater than 2 mm, but fails to reduce the number of small tumors with a diameter less than 2 mm or decrease the incidence of colon tumors. These results suggest that PL may be an effective drug for the treatment of colitis and colorectal cancer, especially in controlling inflammation and the development of large tumors. However, further research is still required for the treatment of human colitis and colorectal cancer.